Estradiol 3-benzoate

• Identification
• Experimental evidence
• Physicochemical properties
• ADMET properties
• Chemical-gene interaction
• Descriptors
• Presence in chemical regulation or guideline
• Presence in human biospecimen

Literature identifier	Study type	Test dosage	Effective dosage	Endocrine-mediated endpoints	Systems-level perturbations
PMID:11849735	IVR	0.5 mg	0.5 mg	Decreased liver weights	Hepatic endocrine-mediated perturbations
	IVR	0.5 mg	0.5 mg	Increased uterine weights	Reproductive endocrine-mediated perturbations
	IVR	0.5 mg	0.5 mg	Changes in morphology of pituitary gland	Neurological endocrine-mediated perturbations
	IVR	0.5 mg	0.5 mg	Increase in T3 levels	Metabolic endocrine-mediated perturbations
	IVR	0.5 mg	0.5 mg	Decrease in T4 levels	Metabolic endocrine-mediated perturbations
PMID:15501383	IVR	0.0125 - 0.5 mg	0.125 - 0.5 mg	Abnormal sperm morphology	Reproductive endocrine-mediated perturbations
	IVR	0.00625 - 0.125 mg	0.0313 - 0.125 mg	Abnormal sperm morphology	Reproductive endocrine-mediated perturbations
PMID:17443786	IVR	0.01 mg	0.01 mg	Affects sexual behavior	Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations
	IVR	0.01 mg	0.01 mg	Affects neural development	Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations
PMID:18025854	IVR	0.025 mg	0.025 mg	Alteration in prostate morphology	Reproductive endocrine-mediated perturbations
	IVR	0.025 mg	0.025 mg	Cancer phenotype	Endocrine-mediated cancer
	IVR	0.025 mg	0.025 mg	Decreased prostate weights	Reproductive endocrine-mediated perturbations
	IVR	0.025 mg	0.025 mg	Affects expression of estrogen receptor-beta (ER-beta)	Reproductive endocrine-mediated perturbations
	IVR	0.025 mg	0.025 mg	Affects expression of androgen receptor (AR)	Reproductive endocrine-mediated perturbations
	IVR	0.025 mg	0.025 mg	Increased testosterone levels	Reproductive endocrine-mediated perturbations
PMID:18656497	IVR	0.05 mg	0.05 mg	Affects neuronal density	Neurological endocrine-mediated perturbations
	IVR	0.05 mg	0.05 mg	Alterations in vaginal opening	Reproductive endocrine-mediated perturbations
	IVR	0.05 mg	0.05 mg	Affects sexual behavior	Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations
	IVR	0.05 mg	0.05 mg	Abnormal estrous cycles	Reproductive endocrine-mediated perturbations
PMID:19442818	IVR	0.025 mg	0.025 mg	Abnormal neuronal distribution	Neurological endocrine-mediated perturbations
PMID:19903717	IVR	0.2 mg/kg/day	0.2 mg/kg/day	Affects steroidogenesis	Reproductive endocrine-mediated perturbations
	IVR	0.2 mg/kg/day	0.2 mg/kg/day	Induce apoptosis of spermatogenic cells	Reproductive endocrine-mediated perturbations
	IVR	0.2 mg/kg/day	0.2 mg/kg/day	Decreased FSH levels	Reproductive endocrine-mediated perturbations
PMID:22016562	IVR	1 mg/kg	1 mg/kg	Affects the normal functioning of reproductive system	Reproductive endocrine-mediated perturbations
	IVR	1 mg/kg	1 mg/kg	Abnormal estrous cycles	Reproductive endocrine-mediated perturbations
	IVR	1 mg/kg	1 mg/kg	Decreased estradiol levels	Reproductive endocrine-mediated perturbations
PMID:22334722	IVR	0.00125 mg/day	0.00125 mg/day	Affects testicular function	Reproductive endocrine-mediated perturbations
	IVR	0.00125 mg/day	0.00125 mg/day	Induce apoptosis in testis	Reproductive endocrine-mediated perturbations
	IVR	0.00075 mg/day	0.00075 mg/day	Affects testicular function	Reproductive endocrine-mediated perturbations
	IVR	0.0025 mg/day	0.0025 mg/day	Affects testicular function	Reproductive endocrine-mediated perturbations
	IVR	0.0025 mg/day	0.0025 mg/day	Induce apoptosis in testis	Reproductive endocrine-mediated perturbations
	IVR	0.0025 mg/day	0.0025 mg/day	Changes in morphology of seminiferous tubules	Reproductive endocrine-mediated perturbations
	IVR	0.025 mg/day	0.025 mg/day	Testicular atrophy	Reproductive endocrine-mediated perturbations
PMID:24284824	IVR	0.05 mg/kg	0.05 mg/kg	Delayed puberty	Reproductive endocrine-mediated perturbations
	IVR	0.05 mg/kg	0.05 mg/kg	Abnormal estrous cycles	Reproductive endocrine-mediated perturbations
	IVR	0.05 mg/kg	0.05 mg/kg	Causes masculinized behavior	Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations
	IVR	0.05 mg/kg	0.05 mg/kg	Affects neural development	Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations
PMID:26190835	IVR	0.05 mg/kg	0.05 mg/kg	Affects sexual behavior	Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations
	IVR	0.05 mg/kg	0.05 mg/kg	Affects neural development	Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations
PMID:27762633	IVR	0.00075 - 0.025 mg/day	0.00075 - 0.025 mg/day	Affects testis development	Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations
	IVR	0.00075 - 0.025 mg/day	0.00075 - 0.025 mg/day	Induce apoptosis of spermatogenic cells	Reproductive endocrine-mediated perturbations
PMID:29458364	IVR	0.05 mg/kg	0.05 mg/kg	Affects anogenital distance in offspring	Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations

---

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.